Medical Affairs Department
Dedicated to providing up-to-date resources, content, and educational materials to support health innovation that makes a difference. Through our commitment to education and resource sharing, we aim to empower healthcare providers with knowledge that supports innovative, impactful health solutions.
Meet Kaitlin Anstett, the Director for Medical Affairs at Theratechnologies as she welcomes you to our medical education page. Here, you can find the latest data on our medicines communicated through posters, papers, and videos by both our team and real providers treating people living with HIV. You can connect with us via email, or through our in-person events listed below. We hope you find the information contained on this page useful. Thank you for visiting.
Featured
People with HIV (PWH) experience accelerated aging, including faster declines in physical function when compared to those without HIV. Although multifactorial, age-related loss of skeletal muscle mass is a significant contributor to this functional decline. In this analysis from the The Visceral Adiposity Measurement and Observations Study (VAMOS) presented at ACTHIV 2025 in Chicago, IL, the authors demonstrate that increased levels of visceral fat are associated with reduced muscle quality to a greater extent than increasing BMI or subcutaneous fat among PWH on modern antiretroviral regimens, which may amplify agerelated declines in muscle quality and quantity.
Presented at ACTHIV 2025 in Chicago, IL, this poster discusses 7 real-world cases of the use of glucagon-like peptide-1 receptor agonists (GLP1-RAs) and tesamorelin in combination in people living with HIV and excess visceral adiposity. These data show a high effectiveness for the combination of tesamorelin and GLP-1-RAs in a real-world setting, with most participants showing reductions in weight, BMI and waist circumference after 6 months of combination therapy.
The latest data from the PROMISE-US registry, a study of the real-world use of ibalizumab in heavily treatment experienced persons with multidrug resistant HIV, was presented at the Conference on Retroviruses and Opportunistic Infections (CROI) on March 12, 2025, in San Francisco, California. Check out this video below to hear from the presenting author, Dr. Smitha Gudipati, and principal investigator of the PROMISE-US study, Dr. Princy Kumar, as they discuss the results and their clinical impact. You can also view and download the poster.
Recent studies demonstrate substantial weight gain among persons with HIV starting modern antiretroviral regimens, and recent evidence presented at the Conference on Retroviruses and Opportunistic Infections (CROI) on March 12, 2025, in San Francisco, California suggests that body mass index is a poor surrogate for excess visceral adiposity and cardiovascular risk in this population. Click below to read more about the study in the American Medical Journal, and to view the poster presentation from CROI.
A real-world case series on the use of ibalizumab and lenacapavir in patients with multidrug-resistant HIV-1 infection presented at ACTHIV 2024
Medical Affairs Events
Literature
Recently published in JAIDS
People living with multidrug-resistant (MDR) HIV-1 have limited treatment options and poor clinical outcomes. TMB-311 was a multicenter, open-label, expanded access phase 3 study that provided a compassionate bridge to commercial availability of ibalizumab for patients with and without prior exposure to drug. Long-term ibalizumab treatment in combination with an optimized background regimen was considered safe and well tolerated with no new safety signals identified in people living with MDR HIV-1. Additionally, ibalizumab-naïve patients experienced notable and early reductions in viral load with sustained increases in CD4+ cell counts over 24 weeks.
Highlighting new science
Long-term ibalizumab + OBR provides sustained reductions in viral load and is a well-tolerated treatment option for treatment-experienced patients with multidrug-resistant HIV-1
Highlighting new science
Ibalizumab plus optimized background regimen resulted in rapid and sustained virological suppression
Published in JAIDS
Rapid and sustained reductions in viral load achieved with ibalizumab plus optimized background regimen in treatment-experienced HIV-positive individuals in the TMB-202 study
Ibalizumab plus optimized background regimen results in rapid and sustained virologic suppression. It was well tolerated, with adverse events generally mild to moderate. Ibalizumab combined with an optimized background regimen may provide a safe and effective treatment option for patients who are multidrug resistant with clinically advanced HIV.
Theratechnologies’ Science at Infectious Disease Week 2024
Although treatment for HIV has advanced considerably over the decades, there are still people with HIV that is resistant to multiple antiretroviral therapies (ART). Ibalizumab, a humanized IgG4 monoclonal antibody that gained FDA approval in 2018, is a post-attachment inhibitor whose efficacy for people with multidrug-resistant (MDR) HIV has been demonstrated in Phase II and III trials.
Download AMJ - Ibalizumab’s Role in Multidrug-Resistant HIVDownload AMJ - The Unseen Impact of Visceral Fat
Original source: https://www.emjreviews.com/en-us/amj/microbiology-infectious-diseases/symposium/ibalizumabs-role-in-multidrug-resistant-hiv-j100124/
Original source: Original source: https://www.emjreviews.com/en-us/amj/microbiology-infectious-diseases/symposium/reducing-cardiovascular-risk-in-hiv-the-unseen-impact-of-visceral-fat-j100124/
© 2025 - This landing page is intended for US healthcare professionals only. This page was funded and developed by Theratechnologies.
Privacy Policy